Innovative Diagnostics Cisbio specializes in high-quality assays for in vitro diagnostics, particularly targeting cancer, metabolic, and auto-immune diseases. This focus presents sales opportunities with pharmaceutical and clinical laboratories seeking cutting-edge diagnostic tools and services.

Global Presence With facilities in France, the USA, Japan, and China, Cisbio’s worldwide operations enable it to engage with international biotech, pharma, and research markets, providing avenues for expanding regional sales collaborations and localized product offerings.

Technology Leadership Cisbio’s proprietary HTRF technology positions it as a leader in fluorescence detection methods, making it a compelling partner for companies aiming to incorporate advanced assay technologies into their drug discovery and research pipelines.

Acquisition Benefits As part of PerkinElmer, Cisbio can leverage broader distribution channels, enhanced R&D resources, and increasing brand recognition, which can support upselling and cross-selling of sophisticated biotech solutions to existing and new customers.

Funding and Growth While specific funding data is unavailable, the company’s revenue in the $10M - 25M range indicates a solid financial foundation with room for growth, creating opportunities to pitch innovative biotech products, additional assays, and custom services to expand market share.